Endocrinology (all articles)
RCT | Verapamil partially preserved pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes
27 Feb, 2023 | 13:14h | UTCSummary: The study aimed to determine whether verapamil could preserve pancreatic beta cell function in children and adolescents with newly diagnosed type 1 diabetes. The randomized clinical trial involved 88 participants who were given either verapamil or placebo once daily for 52 weeks. The study found that C-peptide levels were 30% higher in the verapamil group compared to the placebo group at 52 weeks, and the percentage of participants with a 52-week peak C-peptide level of 0.2 pmol/mL or greater was 95% in the verapamil group compared to 71% in the placebo group. The study also found that verapamil was well tolerated with few adverse events. The results suggest that verapamil may partially preserve stimulated C-peptide secretion in children and adolescents with newly diagnosed type 1 diabetes. However, further studies with patient-relevant outcomes are needed to determine the long-term effectiveness and the optimal length of therapy.
Article: Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Preserving Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes – JAMA (free for a limited period)
News Release: Verapamil shows beneficial effect on the pancreas in children with newly-diagnosed type 1 diabetes – University of Minnesota
Commentary on Twitter
In youth with newly diagnosed type 1 diabetes, verapamil partially preserved stimulated C-peptide secretion at 52 weeks from diagnosis compared with placebo. https://t.co/m4xbczf93C #ATTD2023 pic.twitter.com/teM0jjh1tT
— JAMA (@JAMA_current) February 24, 2023
Cohort Study | Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein
27 Feb, 2023 | 12:44h | UTCLipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein – European Heart Journal (link to abstract – $ for full-text)
Commentary: Lp(a) Is Linked to Atherothrombosis Independent of CRP – American College of Cardiology
Consensus Statement | Standardized imaging and reporting for thyroid ultrasound
24 Feb, 2023 | 13:52h | UTCRelated: ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee
Cohort Study | Association of large-for-gestational age birth and prediabetes/diabetes 10-14 years’ postpartum
24 Feb, 2023 | 13:43h | UTCSummary: Several studies show that women who develop diabetes during pregnancy are at increased risk of developing diabetes later in life. This study investigated whether giving birth to a larger-than-normal baby is associated with an increased risk of prediabetes or diabetes 10-14 years after pregnancy in individuals without gestational diabetes. The study used data from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Follow-up Study, including pregnant individuals without gestational diabetes. After adjusting for various baseline maternal characteristics, the researchers found that individuals who gave birth to a large-for-gestational age (LGA) infant had a 21% higher risk of being diagnosed with prediabetes or diabetes 10-14 years after delivery compared to those who had an appropriate-for-gestational age (AGA) infant. The study concluded that having a previous LGA infant is a marker of increased risk of developing prediabetes or diabetes in individuals without gestational diabetes.
Abstract: Association of large-for-gestational age birth and prediabetes/diabetes 10-14 years’ postpartum in the HAPO follow-up study – American Journal of Obstetrics & Gynecology (link to abstract, presented at the Society for Maternal-Fetal Medicine’s annual meeting)
Commentaries:
Delivering a Plus-Sized Baby Could Be Sign of Diabetes Risk – HealthDay
Large for Gestational Age Births Could Increase Diabetes Risk in Women – HCP Live
M-A | Low-dose insulin infusion is safe and effective in treating diabetic ketoacidosis in children
23 Feb, 2023 | 13:40h | UTCSummary: The article discusses a systematic review and meta-analysis of randomized controlled trials comparing low-dose insulin at 0.05 units/kg/hr to standard dose at 0.1 units/kg/hr for children with diabetic ketoacidosis (DKA). The study found that low-dose insulin infusion is probably as efficacious and safer than standard-dose insulin in treating DKA in children, as it has no effect on the time to resolution of hyperglycemia or acidosis and probably reduces the risk of developing hypokalemia and hypoglycemia. However, the results are limited by imprecision and generalizability to other settings since all studies were performed in a single country. Therefore, further studies are required to identify the optimal insulin dose for children with DKA in terms of safety and effectiveness.
M-A | Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics
23 Feb, 2023 | 13:26h | UTCSummary: This study aimed to evaluate the mid- to long-term metabolic side effects of 31 antipsychotics in persons with schizophrenia by analyzing 137 eligible randomized controlled trials with 35,007 participants. The primary outcome was weight gain, with secondary outcomes including fasting glucose, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides. The study found that antipsychotic drugs differ in their propensity to induce metabolic side effects. Chlorpromazine, clozapine, olanzapine, and zotepine produced the most weight gain. The confidence in the evidence ranged from low to moderate. The study suggests that differences in weight gain were more pronounced than previously published short-term data and that weight gain is most pronounced at the beginning of treatment and then remains stable.
Article: Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics: a network meta-analysis of randomized controlled trials – World Psychiatry (free for a limited period)
M-A | Sugar-sweetened beverage consumption and weight gain in children and adults
22 Feb, 2023 | 12:26h | UTC
Trends and predictions of malnutrition and obesity in 204 countries and territories: an analysis of the Global Burden of Disease Study 2019
22 Feb, 2023 | 12:17h | UTC
Review | Diagnosis and management of patients with polyneuropathy
21 Feb, 2023 | 11:40h | UTCDiagnosis and management of patients with polyneuropathy – Canadian Medical Association Journal
RCT | Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease
20 Feb, 2023 | 12:27h | UTCSummary: The article reports on a randomized trial that compared the effects of alternate-day fasting (ADF) combined with exercise, fasting alone, or exercise alone in adults with obesity and non-alcoholic fatty liver disease (NAFLD). After three months, the combination of ADF and exercise significantly reduced intrahepatic triglyceride content, body weight, fat mass, waist circumference, and alanine transaminase levels compared to the control group. The intervention seems promising for patients with fatty liver disease who want to improve their health without using medications.
Article: Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: A randomized controlled trial – Cell Metabolism (link to abstract – $ for full-text)
News Release: Alternate-day fasting could be a good option for patients with fatty liver disease – University of Illinois Chicago
M-A | Consumption of whole vs. refined grains and risk of cardiovascular disease and all-cause mortality
20 Feb, 2023 | 12:23h | UTCSummary: This systematic review and meta-analysis of prospective cohort studies found that consuming whole grains was associated with a reduced risk of coronary heart disease, cardiovascular disease, and all-cause mortality, while consuming refined grains had no significant influence on these outcomes. Residual confounding can’t be excluded and the association found does not necessarily imply causation.
M-A | Soluble fiber supplementation and serum lipid profile
20 Feb, 2023 | 12:18h | UTCSummary: The article presents the results of a systematic review and dose-response meta-analysis of randomized controlled trials (RCTs) that evaluated the effect of soluble fiber supplementation on blood lipid parameters in adults. The review included 181 RCTs with 220 treatment arms and 14,505 participants. The meta-analysis found that soluble fiber supplementation significantly reduced LDL cholesterol, total cholesterol, triglycerides, and apolipoprotein B concentrations. The article suggests that increasing fiber intake using soluble fiber supplementation could be an effective intervention in the prevention and management of dyslipidemia, and consequently may contribute to the risk reduction of cardiovascular diseases. However, the article also notes that because of the high between-study heterogeneity and publication bias, the findings should be interpreted cautiously.
M-A | Aspirin with or without statin in individuals without atherosclerotic CVD across risk categories
17 Feb, 2023 | 13:22h | UTCSummary: This meta-analysis examined the effects of aspirin in adults without atherosclerotic cardiovascular disease (ASCVD), stratified by statin use across different ASCVD risks. The analysis found that aspirin reduced myocardial infarction but increased major bleeding, and was not associated with total or cardiovascular survival benefits. In adults without ASCVD, concomitant statin appeared to significantly reduce absolute risk reduction for MI associated with aspirin without influencing bleeding risk. The study highlights that the risk-benefit equilibrium may be tilted towards more harm for primary prevention, and that the expected absolute risk of major bleeding exceeds absolute MI benefits by aspirin for every level of ASCVD risk. The findings have implications for the use of aspirin in those already on statin therapy for primary ASCVD prevention.*
*Note: This summary was created through the collaboration of a medical editor and ChatGPT.
Perspective | A short history of saturated fat: the making and unmaking of a scientific consensus
16 Feb, 2023 | 14:57h | UTC
Commentary from the author on Twitter (thread – click for more)
My latest: "A short history of saturated fat: the making and unmaking of a scientific consensus"
Do saturated fats cause heart disease? The science was always weak. Fear of these fats was started by American Heart Assoc. in 1961 based on a flawed study?https://t.co/J3cOlfzTi6— Nina Teicholz (@bigfatsurprise) December 14, 2022
Cohort Study | Associations between types and sources of dietary carbohydrates and cardiovascular disease risk
15 Feb, 2023 | 16:13h | UTCSummary: This study found that the associations between carbohydrate intake and cardiovascular disease risk depend on the type and source of carbohydrates consumed, with free sugar intake being associated with higher risk of total cardiovascular disease and stroke. Fiber intake was associated with lower risk, and replacing refined grain starch and free sugars with wholegrain starch and non-free sugars may be protective for cardiovascular disease. Free sugar intake was also associated with higher triglycerides and lipoprotein subclasses. As with all observational studies, this study cannot establish causality, but rather suggests associations between carbohydrate intake and cardiovascular disease risk, and the importance of considering the quality of carbohydrates consumed for cardiovascular health.*
News Release: Free sugars associated with higher risk of cardiovascular disease – BioMed Central
*Note: This summary was created through the collaboration of a medical editor and ChatGPT.
SR | Preoperative medical treatments and surgical approaches for acromegaly
15 Feb, 2023 | 15:48h | UTC
Position Statement | Immune checkpoint inhibitors and endocrine disorders
14 Feb, 2023 | 10:50h | UTCRelated:
Updated Guideline | Cardiovascular disease risk assessment and reduction, including lipid modification
13 Feb, 2023 | 12:47h | UTCRelated Guidelines:
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease – Circulation
#ESCCongress – 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias
#ESCCongress – 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.
Abbreviated lipid guidelines for clinical practice
13 Feb, 2023 | 12:46h | UTCOriginal Guidelines
#ESCCongress – 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias
#ESCCongress – 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.
Related:
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease – Circulation
Consensus Statement | Evaluation and management of patients with diabetes and heart failure
10 Feb, 2023 | 13:51h | UTCRelated:
ACC/AHA/HFSA 2022 and ESC 2021 guidelines on heart failure comparison – ESC Heart Failure
#ACC22 – 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.
M-A | Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus
10 Feb, 2023 | 13:38h | UTC
Cohort Study | The impact of population-level HbA1c screening on reducing diabetes diagnostic delay in middle-aged adults
9 Feb, 2023 | 13:28h | UTC
Review | Management of menopausal symptoms
8 Feb, 2023 | 12:44h | UTCManagement of Menopausal Symptoms: A Review – JAMA (free for a limited period)
Audio Clinical Review: Treatment of Menopausal Symptoms – JAMA
Research shows ad libitum meal energy intake is influenced by energy density, eating rate and hyper-palatable foods
8 Feb, 2023 | 12:36h | UTCAd libitum meal energy intake is positively influenced by energy density, eating rate and hyper-palatable food across four dietary patterns – Nature Food (free for a limited period)
News Release: Research shows impact of ‘hyper-palatable’ foods across four diets – University of Kansas
Commentary from one of the authors on Twitter (thread – click for more)
What determines how many calories people eat during a meal? Our new study, led by Tera Fazzino @UnivOfKansas, was just published in @NatureFoodJnl & investigated the meal characteristics that influence ad libitum energy intake. https://t.co/Of2IzddLRd
— Kevin Hall (@KevinH_PhD) January 30, 2023
RCT | Outcomes in children of women with type 2 diabetes exposed to metformin vs. placebo during pregnancy
8 Feb, 2023 | 12:32h | UTCOutcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)